肾移植术后早期严重肺部感染患者外周血CD4+T淋巴细胞计数的临床意义

Objective To explore the clinical implication of peripheral blood CD4+ T-cell counts in renal allograft recipients with severe pulmonary infection in the early stage after kidney transplantation. Methods From February 2007 to June 2008, we investigated the variation of peripheral blood CD4+ T-cell counts using flow cytometry in 28 cases of severe pulmonary infection 1 ～6 months after kidney transplantation (infection group), and 30 cases (control group) randomly selected that had stable situation and normal kidney function in the same period. Results CD4+ T-cell counts on the day of admission in infection group were significantly lower than in control group (184.1 ±117.5/μl vs. 518.6±232.7/μl, P<0.01 ). In infection group, 5 patients died and 4 of them had obviously declining trends of CD4+ T-cell counts during hospitalization course. Comparing to the day of admission, CD4+ T-cell counts of those survivors in infection group were significantly increased (184.1±117.5/μl vs. 406.5±163.9/μl, P<0.01) when infections were controlled. ROC analysis showed that CD4+ T-cell counts on the day of admission were accurate enough to identify who were susceptible to infection. In detail, the area under the curve (AUC) was 94.9% (P<0.01). CD4+ T-cell counts of 220/μl displayed the minimal misdiagnosis rate. Conclusions The variations of CD4+ T-cell counts are correlated to onset and progression of severe pulmonary infection in the early stage after kidney transplantation. Those who had CD4+ T-cell counts lower than 220/μl were at high risk of pulmonary infection. Direct measure and dynamic analysis of CD4+ T-cell subset have an important role in optimizing treatment and predicting prognosis of severe pulmonary infection in the early stage after kidney transplantation.     

肾移植术后早期严重肺部感染患者外周血CD4+T淋巴细胞计数的临床意义

Objective To explore the clinical implication of peripheral blood CD4+ T-cell counts in renal allograft recipients with severe pulmonary infection in the early stage after kidney transplantation. Methods From February 2007 to June 2008, we investigated the variation of peripheral blood CD4+ T-cell counts using flow cytometry in 28 cases of severe pulmonary infection 1 ～6 months after kidney transplantation (infection group), and 30 cases (control group) randomly selected that had stable situation and normal kidney function in the same period. Results CD4+ T-cell counts on the day of admission in infection group were significantly lower than in control group (184.1 ±117.5/μl vs. 518.6±232.7/μl, P<0.01 ). In infection group, 5 patients died and 4 of them had obviously declining trends of CD4+ T-cell counts during hospitalization course. Comparing to the day of admission, CD4+ T-cell counts of those survivors in infection group were significantly increased (184.1±117.5/μl vs. 406.5±163.9/μl, P<0.01) when infections were controlled. ROC analysis showed that CD4+ T-cell counts on the day of admission were accurate enough to identify who were susceptible to infection. In detail, the area under the curve (AUC) was 94.9% (P<0.01). CD4+ T-cell counts of 220/μl displayed the minimal misdiagnosis rate. Conclusions The variations of CD4+ T-cell counts are correlated to onset and progression of severe pulmonary infection in the early stage after kidney transplantation. Those who had CD4+ T-cell counts lower than 220/μl were at high risk of pulmonary infection. Direct measure and dynamic analysis of CD4+ T-cell subset have an important role in optimizing treatment and predicting prognosis of severe pulmonary infection in the early stage after kidney transplantation.     

肾移植术后早期严重肺部感染患者外周血CD4+T淋巴细胞计数的临床意义

Objective To explore the clinical implication of peripheral blood CD4+ T-cell counts in renal allograft recipients with severe pulmonary infection in the early stage after kidney transplantation. Methods From February 2007 to June 2008, we investigated the variation of peripheral blood CD4+ T-cell counts using flow cytometry in 28 cases of severe pulmonary infection 1 ～6 months after kidney transplantation (infection group), and 30 cases (control group) randomly selected that had stable situation and normal kidney function in the same period. Results CD4+ T-cell counts on the day of admission in infection group were significantly lower than in control group (184.1 ±117.5/μl vs. 518.6±232.7/μl, P<0.01 ). In infection group, 5 patients died and 4 of them had obviously declining trends of CD4+ T-cell counts during hospitalization course. Comparing to the day of admission, CD4+ T-cell counts of those survivors in infection group were significantly increased (184.1±117.5/μl vs. 406.5±163.9/μl, P<0.01) when infections were controlled. ROC analysis showed that CD4+ T-cell counts on the day of admission were accurate enough to identify who were susceptible to infection. In detail, the area under the curve (AUC) was 94.9% (P<0.01). CD4+ T-cell counts of 220/μl displayed the minimal misdiagnosis rate. Conclusions The variations of CD4+ T-cell counts are correlated to onset and progression of severe pulmonary infection in the early stage after kidney transplantation. Those who had CD4+ T-cell counts lower than 220/μl were at high risk of pulmonary infection. Direct measure and dynamic analysis of CD4+ T-cell subset have an important role in optimizing treatment and predicting prognosis of severe pulmonary infection in the early stage after kidney transplantation.     

儿童肾移植后应用他克莫司为主的免疫抑制方案的临床观察

目的 总结儿童肾移植受者术后应用以他克莫司(Tac)为主的免疫抑制方案的体会.方法 35例受者,年龄为(12.4±1.5)岁(10～18岁),均接受成人尸体供肾,其中33例为首次肾移植,2例为再次肾移植.所有受者肾移植后均采用Tac、霉酚酸酯(MMF)和糖皮质激素预防排斥反应.术后3个月内、3～6个月、6～12个月时Tac的用量分别为0.15～0.32 mg·kg-1·d-1、0.12～0.15 mg·kg-1·d-1、0.07～0.11 mg·kg-1·d-1,Tac浓度谷值分别为(10.5±1.4)μg/L、(8.5±0.8)μg/L、(7.2±0.5)μg/L.35例中,18例术前进行免疫诱导治疗.结果 术后移植肾1、3、5年存活率分别为100%、97.1%、93.9%,受者1、3、5年存活率分别为100%、94.1%、90.9%.术后第1年受者的体重增加了(6.6±2.2)kg,身高增加了(3.7±1.1)cm.术后共有7例(20.0%,7/35)发生急性排斥反应.治疗后均逆转.其他并发症包括高血压11例(31.4%),高血脂5例(14.3%).药物性肝损伤4例(11.4%),肺部感染4例(11.4%),骨髓抑制2例(5.7%),糖尿病2例(5.7%),单纯性疱疹1例(2.8%),受者均无牙龈增生及多毛症.结论 儿童肾移植受者采用Tac、MMF和糖皮质激素预防排斥反应有效,应注意Tac和激素的用量和用法.术前行免疫诱导治疗对降低急性排斥反应的发生有益.     

CYP3A5和MDR1基因型对尿毒症患者肾移植术后早期他克莫司血药浓度和肌酐水平的影响

目的 评价真实临床实践中CYP3A5(CYP3A5*3,6986A>G)及MDR1(C3435>T,G2677>T/A,C1236>T)基因多态性对尿毒症患者接受肾移植术后早期他克莫司血药浓度的影响及其最佳治疗浓度.方法 以入选2013～2017年单中心的131例首次肾移植术且术后以他克莫司为基础进行三联免疫治疗的患者...     

羟苯磺酸钙在肾移植后肾功能不全患者中的应用

我们对60例肾移植后移植肾功能不全的患者应用了羟苯磺酸钙进行治疗,并观察其临床效果,报告如下.     

肾移植术后合用硫唑嘌呤和霉酚酸酯致严重粒细胞缺乏一例

肾移植术后,应用硫唑嘌呤和霉酚酸酯常会引起骨髓抑制,严重时可致粒细胞缺乏(中性粒细胞绝对计数<0.5×109/L),因此,临床上两者不可合用.本院1例肾移植受者于术后4年时,自行合用硫唑嘌呤和霉酚酸酯,发生严重粒细胞缺乏.现报道如下.     

再次肾移植115例疗效观察及影响因素分析

目的:回顾性分析115例再次肾移植患者的临床资料,观察再次肾移植的效果并分析其影响因素.方法:回顾性分析我院自1978年7月至2006年10月间115例再次肾移植术后人/肾1年存活率,并与同期首次移植患者作对比;分析首次移植失败原因、血透过渡时间、术前补体依赖性细胞毒性试验(CDC)、群体反应性抗体(PRA)水平、免疫抑制方案等因素对移植术后效果的影响.结果:再次移植组术后移植肾1年存活率明显低于首次移植组(69.6% vs 88.7%,P＜0.05).血透过渡时间＜6个月组患者移植肾功能恢复正常的比率明显高于6～12个月、12～24个月、＞24个月各组(P＜0.05);CDC＜5%组移植肾存活率明显高于5%～10%及＞10%组(72% vs 31% vs 0,P＜0.05);再次肾移植受者PRA＜10%组术后急性排斥反应发生率明显低于PRA＞10%组(30.2% vs 75.0%),而移植肾1年存活率明显高于后者(74.4% vs 60.0%,P＜0.05);免疫抑制方案中应用抗体诱导组术后移植肾1年存活率明显高于未用抗体诱导组(81.0% vs 63.4%,P＜0.05).结论:再次移植肾存活率低于首次移植;首次肾移植失败原因、血透过渡时间、术前PRA水平、术前淋巴细胞毒性反应水平及免疫抑制方案均影响再次肾移植效果.